Neurocrine Bio. (NBIX) PT Lowered to $114 at BofA Securities
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/2/2026
- US stocks set for higher open as AI trade steadies; midterms in focus
- Marvell agrees $115 billion all-stock deal to buy Lumentum
- Oil drops 6% as Iran signals openness to peace talks
- Why has the market become so unforgiving of AI earnings?
- EchoStar rises on report SpaceX in talks to buy Boost Mobile or tap its network
Tweet
Share
E-mailGet Alerts NBIX Hot Sheet
Price: $146.22 +0.08%
Rating Summary:
31 Buy, 6 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 19 | Down: 20 | New: 16
Rating Summary:
31 Buy, 6 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 19 | Down: 20 | New: 16
Join SI Premium – FREE
BofA Securities analyst Tazeen Ahmad lowered the price target on Neurocrine Bio. (NASDAQ: NBIX) to $114.00 (from $126.00) while maintaining a Buy rating.
You May Also Be Interested In
- Hartford Financial Services (HIG) PT Lowered to $136 at Cantor Fitzgerald
- Gates Industrial Corp. (GTES) PT Lowered to $27 at DA Davidson
- Federal Signal (FSS) PT Lowered to $126 at DA Davidson
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
